[Form 4] TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity

Rhea-AI Filing Summary

LIEBERMAN GERALD M reported acquisition or exercise transactions in this Form 4 filing.

TEVA PHARMACEUTICAL INDUSTRIES LTD director Gerald M. Lieberman reported a compensation grant of restricted share units. On May 28, 2026, he received 7,242 restricted share units, each linked to one ordinary share. These units vest on May 28, 2027, and he now holds 7,242 units directly.

Each unit represents a contingent right to receive either one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LIEBERMAN GERALD M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	7,242	$0.00	--

Holdings After Transaction: Restricted Share Units — 7,242 shares (Direct, null)

Footnotes (1)

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Key Figures

RSUs granted: 7,242 units Grant price: $0.00 per unit Underlying shares: 7,242 ordinary shares +3 more

6 metrics

RSUs granted 7,242 units Restricted share unit grant on May 28, 2026

Grant price $0.00 per unit Compensation award, not open-market purchase

Underlying shares 7,242 ordinary shares Each RSU linked to one ordinary share

Post-grant RSU holdings 7,242 units Total restricted share units following transaction

Vesting date May 28, 2027 RSUs vest one year after grant

ADS ratio 1 ADS = 1 ordinary share Representation of Teva ordinary shares

Key Terms

Restricted Share Units, Ordinary Shares, American Depositary Shares

3 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value of one ordinary share."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Ordinary Shares financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or the cash value of one ordinary share."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIEBERMAN GERALD M

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	05/28/2026		A		7,242		(2)	(2)	Ordinary Shares(3)	7,242	$0	7,242	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Gerald M. Lieberman	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TEVA director Gerald M. Lieberman report?

Gerald M. Lieberman reported a grant of 7,242 restricted share units as compensation. The grant occurred on May 28, 2026 and gives him contingent rights tied to Teva ordinary shares, subject to future vesting conditions and potential share or cash settlement.

How many TEVA restricted share units were granted and when do they vest?

He received 7,242 restricted share units that vest on May 28, 2027. Vesting means the units become earned at that date, after which they can settle in ordinary shares or cash, based on the Human Resources and Compensation Committee’s decision.

What does each TEVA restricted share unit granted to the director represent?

Each restricted share unit represents a contingent right to receive one ordinary share or the cash value of one ordinary share. Settlement form is determined by the Human Resources and Compensation Committee, aligning compensation with Teva’s equity performance over time.

How many TEVA restricted share units does Gerald M. Lieberman hold after this grant?

Following the grant, he holds 7,242 restricted share units directly. This figure reflects his position in these equity-based awards as reported in the filing, providing insight into his incentive alignment with Teva’s long-term share performance.

How are TEVA ordinary shares related to American Depositary Shares (ADS)?

Teva’s ordinary shares may be represented by American Depositary Shares, and each ADS currently represents one ordinary share. This one-to-one relationship simplifies understanding of the director’s equity-linked awards for investors who trade Teva through ADSs.

Was the TEVA restricted share unit grant an open-market purchase or a compensation award?

The transaction is a compensation-related award, not an open-market purchase. It is coded as a grant or award acquisition, with a per-unit price of $0.00, reflecting equity-based compensation rather than a cash-funded share purchase in the market.